JPH07502484A - 哺乳動物免疫不全ウイルスの検出 - Google Patents
哺乳動物免疫不全ウイルスの検出Info
- Publication number
- JPH07502484A JPH07502484A JP51101692A JP51101692A JPH07502484A JP H07502484 A JPH07502484 A JP H07502484A JP 51101692 A JP51101692 A JP 51101692A JP 51101692 A JP51101692 A JP 51101692A JP H07502484 A JPH07502484 A JP H07502484A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- virus
- fiv
- immunodeficiency virus
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 55
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims abstract description 28
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 27
- 230000007813 immunodeficiency Effects 0.000 title claims abstract description 27
- 238000001514 detection method Methods 0.000 title claims abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000003018 immunoassay Methods 0.000 claims abstract description 12
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 5
- 101710188315 Protein X Proteins 0.000 claims abstract description 5
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 49
- 150000001413 amino acids Chemical class 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 20
- 238000007818 agglutination assay Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 241000282324 Felis Species 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims description 4
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 29
- 230000001900 immune effect Effects 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 description 19
- 241000282326 Felis catus Species 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 14
- 238000003556 assay Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 101710072850 Poxin Proteins 0.000 description 6
- 101710142282 Protein P26 Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012286 ELISA Assay Methods 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000713666 Lentivirus Species 0.000 description 4
- 101800000385 Transmembrane protein Proteins 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 102100034353 Integrase Human genes 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 108010078428 env Gene Products Proteins 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000282323 Felidae Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 241000282372 Panthera onca Species 0.000 description 2
- 241000282373 Panthera pardus Species 0.000 description 2
- 241001313871 Puma Species 0.000 description 2
- 206010038997 Retroviral infections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002788 anti-peptide Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- IITIZHOBOIBGBW-UHFFFAOYSA-N 3-ethyl-2h-1,3-benzothiazole Chemical compound C1=CC=C2N(CC)CSC2=C1 IITIZHOBOIBGBW-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- -1 Boc-amino Chemical class 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- OWNRRUFOJXFKCU-UHFFFAOYSA-N Bromadiolone Chemical compound C=1C=C(C=2C=CC(Br)=CC=2)C=CC=1C(O)CC(C=1C(OC2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OWNRRUFOJXFKCU-UHFFFAOYSA-N 0.000 description 1
- 101710169873 Capsid protein G8P Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102000028180 Glycophorins Human genes 0.000 description 1
- 108091005250 Glycophorins Proteins 0.000 description 1
- 101710170470 Glycoprotein 42 Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282852 Lama guanicoe Species 0.000 description 1
- 241001455213 Leopardus pardalis Species 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710155913 Major envelope protein Proteins 0.000 description 1
- 101710156564 Major tail protein Gp23 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101800001151 Protein p25 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 241000282840 Vicugna vicugna Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- MAHPNPYYQAIOJN-UHFFFAOYSA-N azimsulfuron Chemical compound COC1=CC(OC)=NC(NC(=O)NS(=O)(=O)C=2N(N=CC=2C2=NN(C)N=N2)C)=N1 MAHPNPYYQAIOJN-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Abstract
Description
Claims (14)
- 1.哺乳動物免疫不全ウイルスのエンベロープタンパク質の免疫優性領域のペプ チドであって、該ペプチドはジスルフィドループを含むもの。
- 2.有蹄動物かまたはネコ科の動物のいずれかに感染する免疫不全ウイルス由来 のものである請求項1に記載のペプチド。
- 3.下記配列: 【配列があります】 を有するネコ免疫不全ウイノレスのenvgp40タンパク質のアミノ酸680 −711からの少なくとも8連続アミノ酸からなる請求項1に記載のペプチド。
- 4.下記配列: 【配列があります】 を有するウシ免疫不全ウイルスのenvgp42タンパク質のアミノ酸625− 660からの少なくとも8連続アミノ酸からなる請求項1に記載のペプチド。
- 5.10〜20のアミノ酸からなる請求項3または請求項4に記載のペプチド。
- 6.20〜25のアミノ酸からなる請求項3または請求項4に記載のペプチド。
- 7.25〜35のアミノ酸からなる請求項3または請求項4に記載のペプチド。
- 8.組換えDNA注を用いる工程からなることを特徴とする、請求項1〜7のい ずれか1に記載のペプチドの調製法。
- 9.化学的合成法を用いる工程からなることを特徴とする、請求項1〜7のいず れか1に記載のペプチドの調製法。
- 10.請求項1〜7のいずれか1に記載のペプチドに対して向けられたポリクロ ーナルまたはモノクローナル抗体または免疫学的に機能を有するそのフラグメン トまたは抗体類似体。
- 11.請求項1〜7のいずれか1に記載のペプチドからなる試薬を用いる工程か らなることを特徴とする、該ウイルスに暴露された哺乳動物からの生物学的試料 中の哺乳動物免疫不全ウイルスに対する抗体の検出のためのイムノアッセイ。
- 12.オーストラリア特許出願第22224/88号および第24182/88 号に記載されているように、該凝集アッセイが直接または間接の全血凝集アッセ イである請求項15または請求項16に記載の凝集アッセイ。
- 13.請求項11または請求項12に記載のイムノアッセイを行うための試験キ ット。
- 14.請求項10に記載の抗体からなることを特徴とする、哺乳動物免疫不全ウ イルスに対する免疫吸着体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK671191 | 1991-06-14 | ||
AU6711 | 1991-06-14 | ||
PCT/AU1992/000280 WO1992022573A1 (en) | 1991-06-14 | 1992-06-12 | Detection of mammalian immunodeficiency viruses |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07502484A true JPH07502484A (ja) | 1995-03-16 |
JP3356280B2 JP3356280B2 (ja) | 2002-12-16 |
Family
ID=3775473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51101692A Expired - Lifetime JP3356280B2 (ja) | 1991-06-14 | 1992-06-12 | 哺乳動物免疫不全ウイルスの検出 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5591572A (ja) |
EP (1) | EP0602046B2 (ja) |
JP (1) | JP3356280B2 (ja) |
AT (1) | ATE160358T1 (ja) |
AU (1) | AU667669B2 (ja) |
CA (1) | CA2111325C (ja) |
DE (1) | DE69223250T3 (ja) |
WO (1) | WO1992022573A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228608B1 (en) * | 1991-02-28 | 2001-05-08 | Aquila Biopharmaceuticals, Inc. | Recombinant FIV glycoprotein 160 and P24 gag protein |
GB9219936D0 (en) * | 1992-09-21 | 1992-11-04 | Pitman Moore Inc | Vaccines |
FR2721031B1 (fr) * | 1994-06-09 | 1996-07-26 | Centre Nat Rech Scient | Fragment peptidique spécifique du virus de l'immunodéficience féline (VIF) et son utilisation comme réactif de diagnostic. |
FR2732346B1 (fr) * | 1995-03-27 | 1997-05-30 | Centre Nat Rech Scient | Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications |
US5849303A (en) * | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
US6458528B1 (en) * | 1998-05-15 | 2002-10-01 | Idexx Laboratories, Inc. | Diagnosis of feline immunodeficiency virus infection using ENV/GAG polypeptide markers |
US7094884B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them |
US7094757B2 (en) | 2001-06-22 | 2006-08-22 | Roche Diagnostics Corporation | Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them |
US7244819B2 (en) | 2001-06-22 | 2007-07-17 | Roche Diagnostics Operations, Inc. | Fusion polypeptides, vaccines and compositions of FKBP chaperones and target polypeptides |
US6962982B2 (en) | 2001-06-22 | 2005-11-08 | Roche Diagnostics Corporation | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
FR2828687B1 (fr) * | 2001-08-17 | 2003-12-12 | Hippocampe | Nouveaux peptides et leur utilisation comme medicaments contre l'infection par le fiv chez le chat |
WO2006011919A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
ATE435425T1 (de) * | 2003-09-11 | 2009-07-15 | Idexx Lab Inc | Verfahren zum nachweis des felinen immunschwächevirus |
AU2004304348B2 (en) * | 2003-12-18 | 2009-02-26 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2005080939A2 (en) * | 2004-02-19 | 2005-09-01 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
AU2005267605B2 (en) * | 2004-06-30 | 2009-03-26 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2006011920A1 (en) * | 2004-06-30 | 2006-02-02 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus (fiv) comprising the use of peptides derived from the v3 region of the fiv env protein |
US7291338B2 (en) * | 2005-03-09 | 2007-11-06 | Idexx Laboratories, Inc. | Method and device for detecting feline immunodeficiency virus |
WO2011123781A1 (en) | 2010-04-02 | 2011-10-06 | Idexx Laboratories, Inc. | Detection of feline immunodeficiency virus |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5086002A (en) * | 1987-09-07 | 1992-02-04 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
US4894347A (en) * | 1987-09-17 | 1990-01-16 | Agen Limited | Erythrocyte agglutination assay |
US5177014A (en) * | 1988-12-05 | 1993-01-05 | Idexx Laboratories, Inc. | Monoclonal antibodies to feline-T-lymphotropic lentivirus |
US5219725A (en) * | 1988-12-05 | 1993-06-15 | Idexx Laboratories Incorporated | Monoclonal antibodies to feline-t-lymphotropic lentivirus |
JP3058685B2 (ja) * | 1989-05-08 | 2000-07-04 | アイデックス ラボラトリーズ インコーポレーテッド | ネコt細胞リンパトロピック レンチウィルスのポリペプチド |
US5380830A (en) * | 1989-09-18 | 1995-01-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Molecular clones of bovine immunodeficiency-like virus |
FR2669338A1 (fr) * | 1990-11-21 | 1992-05-22 | Centre Nat Rech Scient | Fragments peptidiques issus de la proteine externe du vif, anticorps antifragments, application de ceux-ci au diagnostic et/ou au traitement de l'immunodeficience feline. |
WO1993001304A1 (en) * | 1991-07-10 | 1993-01-21 | Synbiotics Corporation | Synthetic peptides related to fiv-env proteins |
-
1992
- 1992-06-12 AU AU19739/92A patent/AU667669B2/en not_active Expired
- 1992-06-12 EP EP92912386A patent/EP0602046B2/en not_active Expired - Lifetime
- 1992-06-12 CA CA002111325A patent/CA2111325C/en not_active Expired - Lifetime
- 1992-06-12 DE DE69223250T patent/DE69223250T3/de not_active Expired - Lifetime
- 1992-06-12 JP JP51101692A patent/JP3356280B2/ja not_active Expired - Lifetime
- 1992-06-12 US US08/157,141 patent/US5591572A/en not_active Expired - Lifetime
- 1992-06-12 AT AT92912386T patent/ATE160358T1/de not_active IP Right Cessation
- 1992-06-12 WO PCT/AU1992/000280 patent/WO1992022573A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2111325A1 (en) | 1992-12-23 |
EP0602046A1 (en) | 1994-06-22 |
US5591572A (en) | 1997-01-07 |
JP3356280B2 (ja) | 2002-12-16 |
WO1992022573A1 (en) | 1992-12-23 |
DE69223250T3 (de) | 2008-02-28 |
CA2111325C (en) | 2007-10-23 |
EP0602046B2 (en) | 2007-02-21 |
DE69223250T2 (de) | 1998-04-16 |
ATE160358T1 (de) | 1997-12-15 |
AU667669B2 (en) | 1996-04-04 |
EP0602046B1 (en) | 1997-11-19 |
DE69223250D1 (de) | 1998-01-02 |
AU1973992A (en) | 1993-01-12 |
EP0602046A4 (en) | 1995-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2971034B2 (ja) | リンパ節症/後天性免疫不全症候群ウイルスの抗原 | |
JPH07502484A (ja) | 哺乳動物免疫不全ウイルスの検出 | |
US4663436A (en) | Leukemia-associated virus immunogen, vaccine and assay | |
JP2682959B2 (ja) | エプスタイン・バーウィルス初期抗原(拡散)に関連する合成ポリペプチドおよび抗体 | |
JP2733059B2 (ja) | Htlv−▲iii▼抗体の診断用ペプチド並びにそれらの製造法及び用途 | |
JPS63501716A (ja) | 合成ペプチドおよびaidsおよびarcの診断ならびにワクチン注射へのその使用 | |
JPH01308299A (ja) | Hiv―1感染の診断及び治療に有用な組成物 | |
IE903433A1 (en) | Novel peptides associated with the cd4 binding region of¹gp120 and their methods | |
JPH0751598B2 (ja) | Htlv‐1感染検出用合成ペプチド抗原 | |
JPS62500027A (ja) | エプスタイン、バールウィルス核抗原と免疫反応する抗体を産生する化学的に合成されたポリペプチド | |
JPH01500432A (ja) | Aidsおよびarcのウィルス原因物質に対して免疫化するための組成物および方法 | |
CN114276422B (zh) | 新型冠状病毒s蛋白多肽抗原及其应用 | |
NZ207121A (en) | Synthetic peptides with antigenicity of oncoproteins; antibodies; vaccines and diagnostic agents | |
US6033672A (en) | Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens | |
CA2104285A1 (en) | Recombinant fiv glycoprotein 160 and p24 gag protein | |
US20020081566A1 (en) | Hiv protein epitopes immunologically homologous to hla | |
CA2086922C (en) | Synthetic peptides and mixtures thereof for detecting hiv antibodies | |
EP0326490B2 (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
US4794168A (en) | Leukemia-associated virus immunogen, vaccine and assay | |
JP2004535369A (ja) | 試薬およびワクチンとして使用するための免疫原性hivペプチド | |
FR2612519A1 (fr) | Nouvelles fractions peptidiques inductrices d'anticorps protecteurs contre le virus de la leucemie bovine, procede pour l'obtention de telles fractions, leurs sequences codantes et vaccins realises a partir de ces fractions | |
Torres et al. | SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques | |
US6218102B1 (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
US6210874B1 (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
JP2705791B2 (ja) | Aids関連病の検出のための合成抗原 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081004 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081004 Year of fee payment: 6 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081004 Year of fee payment: 6 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091004 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091004 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101004 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101004 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111004 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121004 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121004 Year of fee payment: 10 |